The DOI matches its Crossref record; 329 of the 331 references it cites were found in a registry or an index.
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Abstract
Glucocorticoids have pleiotropic effects that are used to treat diverse diseases such as asthma, rheumatoid arthritis, systemic lupus erythematosus and acute kidney transplant rejection. The most commonly used systemic glucocorticoids are hydrocortisone, prednisolone, methylprednisolone and dexamethasone. These glucocorticoids have good oral bioavailability and are eliminated mainly by hepatic metabolism and renal excretion of the metabolites. Plasma concentrations follow a biexponential pattern. Two-compartment models are used after intravenous administration, but one-compartment models are sufficient after oral administration.The effects of glucocorticoids are mediated by genomic and possibly nongenomic mechanisms. Genomic mechanisms include activation of the cytosolic glucocorticoid receptor that leads to activation or repression of protein synthesis, including cytokines, chemokines, inflammatory enzymes and adhesion molecules. Thus, inflammation and immune response mechanisms may be modified. Nongenomic mechanisms might play an additional role in glucocorticoid pulse therapy. Clinical efficacy depends on glucocorticoid pharmacokinetics and pharmacodynamics. Pharmacokinetic parameters such as the elimination half-life, and pharmacodynamic parameters such as the concentration producing the half-maximal effect, determine the duration and intensity of glucocorticoid effects. The special contribution of either of these can be distinguished with pharmacokinetic/pharmacodynamic…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because of the short plasma half-life of hydrocortisone (approximately 90 min) (90), multiple dosing is recommended to mimic physiological conditions.”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [90]
In the citing paper
“Moreover, it is also important to screen for concomitant use of other drugs such as antifungals, protease inhibitors, or estrogens given the potential drug–drug interaction resulting in increased glucocorticoid effect (32, 33).”
From Approach to the Patient: Diagnosis of Cushing Syndrome (2022) · cites this paper as [32]
In the citing paper
“When GCs are given intravenously or orally, their pharmacokinetics obey first-order release kinetics [4] with an initial high plasma concentration followed by rapid exponential clearance.”
From Fabrication Principles and Their Contribution to the Superior In Vivo Therapeutic Efficacy of Nano-Liposomes Remote Loaded with Glucocorticoids (2011) · cites this paper as [4]
In the citing paper
“glucocorticoids lead to profound and reproducible gene expression changes (Czock et al, 2005).”
From Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients (2012) · cites this paper as Czock et al, 2005
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
The Steroid and Thyroid Hormone Receptor Superfamily
Evans, R. M. (1988) · Science · doi:10.1126/science.3283939 · Cited by 7,439
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
Role of Transcriptional Activation of IκBα in Mediation of Immunosuppression by Glucocorticoids
Scheinman, R. I., Cogswell, P. C., Lofquist, A. K., & Baldwin, A. S. (1995) · Science · doi:10.1126/science.270.5234.283 · Cited by 1,699
Natural versus adaptive regulatory T cells
Bluestone, J. A., & Abbas, A. K. (2003) · Nature Reviews Immunology · doi:10.1038/nri1032 · Cited by 1,323
Use of Inhaled Corticosteroids and Risk of Fractures
Van Staa, T. P., Leufkens, H. G. M., & Cooper, C. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.3.581 · Cited by 1,308
Use of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263
Dexamethasone in Adults with Bacterial Meningitis
de Gans, J., & van de Beek, D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021334 · Cited by 1,205
Barrat, F. J., Cua, D. J., Boonstra, A., Richards, D. F., Crain, C., Savelkoul, H. F., de Waal-Malefyt, R., Coffman, R. L., Hawrylowicz, C. M., & O'Garra, A. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011629 · Cited by 1,161
Research works printed but not linked: 19
- Rohatagi, 1995, Pharmazie, 50, 610
- Barth, 1992, Int J Clin Pharmacol Ther Toxicol, 30, 317
- Meibohm, 1999, Int J Clin Pharmacol Ther, 37, 367
- Oosterhuis, 1986, J Pharmacol Exp Ther, 239, 919
- Braat, 1992, J Pharmacol Exp Ther, 262, 509
- Oosterhuis, 1984, J Pharmacol Exp Ther, 229, 539
- Luippold, 2001, Arzneimittel Forschung, 51, 911
- Wassner, 1977, Clin Nephrol, 8, 293
- Kasinath, 1990, J Lab Clin Med, 115, 196
- Frauman, 1996, Adverse Drug React Toxicol Rev, 15, 203
- Porges, 1992, J Rheumatol, 19, 1191
- Vreden, 1991, Neth J Med, 39, 153
- Needs, 1988, J Rheumatol, 15, 224
- Bracken, 2002, Cochrane Database Syst Rev, &NA;, CD001046
- Bellomio, 2000, Lupus, 9, 377
- Honma, 1994, Ryumachi, 34, 616
- Gertz, 1995, Leukemia, 9, 2115
- Kirkham, 1991, J Rheumatol, 18, 821
- Zellner, 1996, Eur J Clin Chem Clin Biochem, 34, 585
Cited by
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769
“Because of the short plasma half-life of hydrocortisone (approximately 90 min) (90), multiple dosing is recommended to mimic physiological conditions.”
BackgroundToxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
“Dexamethasone is often chosen in this context because of its excellent CNS penetration (Table 3).(69) We give dexamethasone for grade 3 neurologic toxicities other than headaches lasting more than 24 hours, grade 4 neurologic toxicities of any duration, and for any seizures.”
Edlmann, E., Giorgi-Coll, S., Whitfield, P. C., Carpenter, K. L. H., & Hutchinson, P. J. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0881-y · Cited by 729
“5 h to reach its peak plasma concentration, hence the rapid clinical effect, but despite a short plasma half-life is considered a long-acting steroid with a biological half-life of 36–54 h [95, 116].”
Glucocorticoids and fetal programming part 1: outcomes
Moisiadis, V. G., & Matthews, S. G. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.73 · Cited by 576
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
Schubert, M.-L., Schmitt, M., Wang, L., Ramos, C. A., Jordan, K., Müller-Tidow, C., & Dreger, P. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.478 · Cited by 491
Metadata
- Authors
- Czock, D., Keller, F., Rasche, F. M., & H??ussler, U.
- Affiliations
- University Hospital Ulm (DE)
- Corresponding author
- Keller, Frieder
- Venue
- Clinical Pharmacokinetics
- Published
- 2005
- Volume
- 44
- Issue
- 1
- Pages
- 61-98
- ISSN
- 0312-5963 (ISSN-L)
- OpenAlex
- W2119666961
- Cited by
- 886
- References
- 331
- Citations by year
- 2026: 51 · 2025: 52 · 2024: 58 · 2023: 59 · 2022: 53 · 2021: 69 · 2020: 69 · 2019: 37 · 2018: 34 · 2017: 49 · 2016: 33 · 2015: 36 · 2014: 37 · 2013: 34 · 2012: 38
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- glucocorticoids, pharmacokinetics, pharmacodynamics, methylprednisolone, dexamethasone, prednisolone, cortisol, glucocorticoid receptor, pharmacokinetic-pharmacodynamic modeling, endogenous cortisol, twice-daily dosing, inflammation, immune response
- MeSH terms
- Age Factors, Animals, Drug Interactions, Female, Glucocorticoids, Humans, Male, Sex Factors, Genomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. https://app.cochat.ai/papers/10.2165/00003088-200544010-00003
- The paper
- Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005). Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clinical Pharmacokinetics. https://doi.org/10.2165/00003088-200544010-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.